Equities Analysts Set Expectations for SRPT Q4 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research note issued to investors on Monday, January 27th. William Blair analyst S. Corwin anticipates that the biotechnology company will post earnings per share of $3.60 for the quarter. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.49 per share.

Several other brokerages also recently weighed in on SRPT. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. Robert W. Baird dropped their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Evercore ISI dropped their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Monday. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $114.45 on Thursday. The business’s fifty day moving average price is $122.81 and its 200 day moving average price is $127.50. The firm has a market capitalization of $10.93 billion, a PE ratio of 91.56 and a beta of 0.77. Sarepta Therapeutics has a 12 month low of $102.15 and a 12 month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Institutional Trading of Sarepta Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Teachers Retirement System of The State of Kentucky bought a new position in Sarepta Therapeutics in the second quarter valued at about $4,771,000. Simplify Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after buying an additional 88,474 shares during the period. Geode Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after buying an additional 44,306 shares during the period. Summit Partners Public Asset Management LLC increased its stake in shares of Sarepta Therapeutics by 547.9% in the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after buying an additional 116,800 shares during the period. Finally, Larson Financial Group LLC grew its stake in Sarepta Therapeutics by 1,649.8% during the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.